Part 4 · Crisis, care & the future
Toward a cure
No therapy has yet been shown to cure myasthenia gravis reliably. This module follows the immune chain that makes the harmful antibodies and shows where each research route cuts it, with an evidence label. Press play to move the cut along the chain, or pick a route.
Research reported, not recommended. Many of these results come from small, early or unpublished studies. Whether any person could join a trial or receive one of these treatments is a question for their specialist team.
Schematic: shows where each route acts, not how well it works.
The routes side by side
Negative and halted results
Results that did not work, or worked too little to continue, belong on the map too. They show which cuts did not hold.
Corrections and unverified reports.
- No riliprubart MG trial. The C1s inhibitor riliprubart has data in cold agglutinin disease and phase 3 programmes in CIDP, but no myasthenia gravis trial was found in PubMed or ClinicalTrials.gov on 20 October 2026. The C1s route in MG is an extrapolation, not an MG programme. 108
- MuSK-CAART has no posted results. Its phase 1 (7 enrolled) is listed as completed, with no results on the registry and no peer-reviewed report. 94
- Conflicting trade reports, marked unverified. Two reports of the KYSA-6 anti-CD19 CAR-T phase 2 give different 24-week effects, and two conference reports of the telitacicept China phase 3 give different means. The press releases on the first CAR-T-treated MG patient give different ages (33 and 34). 122,306,360,389,525
What would count as a cure
Remission has a precise meaning
The MGFA research standards define post-intervention categories including complete stable remission, pharmacologic remission and minimal manifestations. 271 The 2020 consensus sets the treatment goal as minimal manifestation status or better, with no more than mild medication side effects. Minimal manifestation status means no symptoms or functional limits but some weakness on examination; remission means no symptoms or signs, and excludes people taking daily cholinesterase inhibitors that help. 381
A 2026 review proposes that a cure would be complete remission without ongoing treatment, with a high chance of success, low relapse risk, repeatability after relapse, proportionate toxicity and cost-effectiveness. 114
Under conventional care, lasting drug-free remission is rare: in 421 people followed about 10 years, 12.2% after thymectomy and 4.3% without reached complete stable remission with all treatment stopped for at least a year. 571
Which category is this?
Describe an imagined person's state. The panel names the published category it matches.
Open questions
These are gaps the research literature itself names. Most of the evidence on this page is expected to change within about three years, as seven registered CAR-T trials with more than 260 patients report between 2026 and 2029. 231,242
The approved treatments these routes build on are covered in The treatment ladder, Complement & FcRn inhibitors and Thymectomy over the years.